Tissue factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type 2 diabetes mellitus

Oman Medical Journal

Volumn 25, Issue 3, 2010, Pages 173-178

  El Hagracy, Rehab S ^a   Kamal, Gihan M ^a   Sabry, Inas M ^a   Saad, Abeer A ^a   El Ezz, Nahla F Abou ^b   Nasr, Hesham A R ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c NATIONAL HEART INSTITUTE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; DIABETIC PATIENT; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTHROMBIN TIME; SMOKING;

EID: 79955564242     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2010.52     Document Type: Article

References (47)

1. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag 2006;2(2):145-152.
2. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998 Apr;137(Suppl):S65-S73.
3. Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999 Apr;22(Suppl 3):C14-C20.
4. Gentile NT, Vaidyula VR, Kanamalla U, DeAngelis M, Gaughan J, Rao AK. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Thromb Haemost 2007 Nov;98(5):1007-1013.
5. Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007 Jun;7(3):223-227.
6. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res 1999 Feb;41(2):323-333.
7. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998 Apr;19(Suppl C):C39-C43.
8. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003 Feb;107(7):973-977.
9. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004 Jun;24(6):1015-1022.
10. Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 2001 Mar;101(5):367-375.
11. Panteleev MA, Zarnitsina VI, Ataullakhanov FI. Tissue factor pathway inhibitor: a possible mechanism of action. Eur J Biochem 2002 Apr;269(8):2016-2031.
12. Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997 Mar;349(9054):769-771.
13. Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 2001 Jul;29(7)(Suppl):S126-S129.
14. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002 May;105(18):e138-e143.
15. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004 Feb;109(4):551-556.
16. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997 Oct;96(7):2262-2271.
17. Sommeijer DW, Hansen HR, van Oerle R, Hamulyak K, van Zanten AP, Meesters E, et al. Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes. J Thromb Haemost 2006 Mar;4(3):574-580.
18. Leurs PB, van Oerle R, Wolffenbuttel BH, Hamulyak K. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost 1997 Mar;77(3):472-476.
19. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992 Aug;3(4):439-449.
20. Lam KS, Ma OC, Bourke C, Chan LC, Janus ED. Genetic influence of the R/Q353 genotype on factor VII activity is overwhelmed by environmental factors in Chinese patients with Type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1998 Jul;41(7):760-766.
21. Koyama T, Ohdama S, Aoki N. Plasma tissue factor reflects endothelial cell injury rather than upregulation of tissue factor expression. Thromb Haemost 1997 Aug;78(2):972.
22. Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J 2004 Mar;25(5):371-376.
23. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002 Oct;8(10):1175-1181.
24. Rao AK, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999 May;48(5):1156-1161.
25. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002 Aug;25(8):1340-1345.
26. Song KS, Kim HK. Plasma levels of tissue factor antigen in patients with non-insulin-dependent diabetes mellitus. Yonsei Med J 2004 Feb;45(1):38-42.
27. Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, et al. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2005 Nov;70(2):110-118.
28. El-Ghoroury EA, El-Din HG, Abdel-Kader M, Ragab S. Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 2008 Jan;19(1):7-13.
29. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002 Apr;22(4):539-548.
30. Pinotti M, Bertolucci C, Portaluppi F, Colognesi I, Frigato E, Foà A, et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005 Mar;25(3):646-649.
31. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, et al. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina. Jpn Circ J 1998 Jun;62(6):419-424.
32. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998 Mar;79(3):495-499.
33. Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study. Int Angiol 2008 Aug;27(4):296-301.
34. Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007 Nov;92(11):4352-4358.
35. Krupinski J, Turu MM, Font MA, Ahmed N, Sullivan M, Rubio F, et al. Increased tissue factor, MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis. Vasc Health Risk Manag 2007;3(4):405-412.
36. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006 Mar;17(1):4-12.
37. Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone 2006;8(Suppl 4):S14-S23.
38. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003 Aug;11(8):950-956.
39. Derosa G, D’Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab 2007 Apr;33(2):129-134.
40. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006 Jul;187(1):161-169.
41. Abdel-Hafiz E, Vaidyula VR, Bagga S, London FS, Boden G, Rao AK. Elevated whole blood tissue factor procoagulant activity in diabetes mellitus. Vitamin E inhibits glucose induced tissue factor activity in vitro. Blood 2002;100:496a.
42. Zawadzki C, Susen S, Richard F, Haulon S, Corseaux D, Jeanpierre E, et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 2007 Dec;195(2):e117-e125.
43. Kaneko T, Wada H, Wakita Y, Minamikawa K, Nakase T, Mori Y, et al. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis 1994 Jun;5(3):385-392.
44. McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 1994 Jun;179(6):1847-1854.
45. Hölschermann H, Terhalle HM, Zakel U, Maus U, Parviz B, Tillmanns H, et al. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Thromb Haemost 1999 Dec;82(6):1614-1620.
46. Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002 Aug;106(8):905-908.
47. Sobol AB, Galar M, Mochecka A, Stańczyk L, Kłoczko J. [Tissue factor and it’s inhibitor in patients up to 50 years of age with ischemic stroke]. Pol Merkur Lekarski 2001 Feb;10(56):92-95.